# A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

> **NCT04668339** · PHASE2 · TERMINATED · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 581 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection
- Corona Virus Infection

## Interventions

- **BIOLOGICAL:** ARCT-021 single dose priming
- **BIOLOGICAL:** ARCT-021 two lower dose priming
- **BIOLOGICAL:** ARCT-021 two higher dose priming
- **BIOLOGICAL:** Placebo (two doses), priming
- **BIOLOGICAL:** Randomized booster
- **BIOLOGICAL:** Placebo booster

## Key facts

- **NCT ID:** NCT04668339
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-07
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 581 (ACTUAL)
- **Why stopped:** A decision was made to terminate the study for operational/business reasons. The study was not terminated for reasons of safety or immunogenicity.
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668339, "A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04668339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*